GlassScriptPhysician profile
Sunil K Lal
NPI 1952320236
$25,900.71
in general payments reported to CMS, 2019-2025
43 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,769 · 2021: $2,388 · 2022: $983 · 2023: $1,472 · 2024: $1,986 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029 · Entertainment: $66.67 · Education: $19.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,028.82 |
| Entertainment | $66.67 |
| Education | $19.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,057.02 | 2019-2025 | |
| Allergan, INC. | $6,403.17 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,636.10 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $1,063.50 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $876.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $800.06 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $529.88 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Romark Laboratories, Lc | $386.94 | 2019-2020 | |
| Genzyme Corporation | $352.30 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $350.69 | 2024-2025 | Voquezna |
| Ucb, INC. | $227.58 | 2019-2020 | |
| Ardelyx, INC. | $212.68 | 2023-2025 | Ibsrela |
| Celgene Corporation | $199.69 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $170.46 | 2019-2020 | |
| Medtronic USA, INC. | $162.50 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $139.09 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $133.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $98.47 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $95.92 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $89.66 | 2020-2023 | Talicia |
| Aimmune Therapeutics, INC. | $76.86 | 2024-2025 | Zenpep |
| Endogastric Solutions, INC | $72.99 | 2023-2024 | Esophyx |
| Nestle Healthcare Nutrition INC. | $69.80 | 2020-2023 | |
| Optos, INC. | $66.67 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Merit Medical Systems INC | $62.81 | 2024-2025 | Esophyx, Big60 Inflation Device |
| Shionogi INC | $60.30 | 2019-2020 | |
| Medtronic, INC. | $58.95 | 2023-2024 | Interstim, Endoflip |
| Celltrion USA INC. | $55.33 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $54.60 | 2019-2024 | Rebyota |
| Mylan Institutional INC. | $42.88 | 2023 | Hulio |
| Shire North American Group INC | $34.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $33.80 | 2020-2024 | |
| Nuvasive, INC. | $32.68 | 2019 | |
| Merck Sharp & Dohme LLC | $32.24 | 2019-2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $31.19 | 2025 | Terlivaz |
| Biocon Biologics INC | $21.47 | 2024 | Hulio |
| La Jolla Pharmaceutical Company | $19.28 | 2023 | Xerava |
| Alfasigma USA, INC. | $17.69 | 2020 | |
| W. L. Gore & Associates, INC. | $16.09 | 2020 | |
| Boston Scientific Corporation | $14.70 | 2021 | |
| Gilead Sciences, INC. | $14.16 | 2019 | |
| Capsovision, INC. | $13.79 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.